Shire’s SHP647 Shows Promise as Potential Ulcerative Colitis Treatment, Study Finds

Shire’s SHP647 Shows Promise as Potential Ulcerative Colitis Treatment, Study Finds
Treatment with SHP647 (also known as PF-00547659) significantly decreased remission rates in a Phase 2 clinical trial of patients with ulcerative colitis, a type of inflammatory bowel disease (IBD). The drug is licensed by Shire and was originally designed by Pfizer. Results of this trial were published in The Lancet with the title, “Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT):

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *